Introduction
============

Breast cancer is the leading cause of cancer-related mortality amongst women worldwide ([@b1-or-0-0-7332]), with a mortality rate of \~627,000 annually estimated in 2018 ([@b2-or-0-0-7332]). Uncontrolled proliferative growth and angiogenesis are two basic cancer hallmarks governing the critical transitions towards malignancy during carcinogenesis ([@b3-or-0-0-7332]). PI3K/PTEN signaling, frequently altered in breast carcinoma ([@b4-or-0-0-7332]), confers a survival advantage to tumor cells ([@b5-or-0-0-7332]). Anillin, encoded by anillin actin-binding protein (*ANLN*), is an actin-binding protein, which has been identified as being involved in the PI3K/PTEN pathway ([@b6-or-0-0-7332],[@b7-or-0-0-7332]). It is an F-actin binding protein, which maintains podocyte cytoskeletal dynamics, cell motility and signaling through its interaction with CD2-associated protein, which stimulates the phosphorylation of AKT at serine 473 ([@b6-or-0-0-7332],[@b8-or-0-0-7332]). The inhibition of PI3K/AKT activity in non-small cell lung cancer cells decreased ANLN stability and reduced nuclear levels, suggesting the critical involvement of ANLN in PI3K/AKT signaling ([@b7-or-0-0-7332]). ANLN also serves a significant role in pulmonary carcinogenesis through PI3K/AKT pathway-dependent nuclear function ([@b7-or-0-0-7332]). The nuclear expression of *ANLN* in tumor cells is independently prognostic of a poor outcome in patients with breast cancer ([@b9-or-0-0-7332],[@b10-or-0-0-7332]), and *ANLN* mutations are suggestive of estrogen receptor-positive breast cancer tumorigenesis and endocrine therapy resistance ([@b11-or-0-0-7332]) due to the hyperactivation of PI3K/PTEN ([@b6-or-0-0-7332]). VEGFR-2, also known as kinase insert domain receptor (KDR), promotes angiogenesis ([@b12-or-0-0-7332],[@b13-or-0-0-7332]). PI3K/PTEN activation enhances VEGF signaling, forming a positive feedback loop leading to uncontrolled progressive signaling in tumor cells ([@b4-or-0-0-7332],[@b5-or-0-0-7332]). This body of evidence is indicative of the potential synergy between *ANLN* and *KDR* influencing breast cancer prognosis.

The majority of breast malignancies are caused by acquired and uncorrected genetic adjustments in somatic genes due to inherited gene shuffling ([@b14-or-0-0-7332]). Single nucleotide polymorphisms (SNPs) represent a predominant genetic variation in the human genome ([@b15-or-0-0-7332]), a large number of which are associated with various types of cancer ([@b16-or-0-0-7332]). *ANLN* undergoes genetic changes, including amplification, deletion and SNP mutations, in patients with several types of cancer; mutation rates vary between 0.2% in clear cell renal cell carcinoma and 19.6% in prostate cancer ([@b17-or-0-0-7332],[@b18-or-0-0-7332]). A total of 27 mutations, including 12 amplifications, two deletions and 13 SNPs, were identified in lung adenocarcinoma ([@b19-or-0-0-7332]). The potential functional genetic variant rs10013228 in *KDR* is a prognostic marker of resected colorectal cancer ([@b20-or-0-0-7332]) and renal cell carcinoma ([@b21-or-0-0-7332]). SNPs rs10020464, rs11941492 and rs12498529 of *KDR* are associated with *KRAS2*-mutated tumors, which are also microsatellite instable and CpG island methylator phenotype-positive ([@b22-or-0-0-7332]), and rs11941492 is significantly associated with the early onset of esophageal adenocarcinoma ([@b23-or-0-0-7332]). The genetic variant rs1870377 of *KDR* is associated with sunitinib-mediated overall survival (OS) rate ([@b24-or-0-0-7332]). However, no SNPs of *KDR* with clinical implications have been reported for breast cancer ([@b25-or-0-0-7332]). In the present study, the potential synergy between *ANLN* and *KDR* and its effect on breast cancer outcome were investigated, and relevant SNPs driving this synergy at the genetic level were identified.

Materials and methods
=====================

### Datasets

A total of 14,481 SNPs for *ANLN* and 11,704 SNPs for *KDR* were retrieved from the dbSNP NCBI database ([@b26-or-0-0-7332]). Among these, 20 SNPs of *ANLN* and 13 SNPs of *KDR* were mapped to the Affymetrix SNP6.0 Array, which was used in The Cancer Genome Atlas (TCGA; <http://cancergenome.nih.gov>). Genotype data of the 33 SNPs covering 501 samples were retrieved from the TCGA. The gene expression and clinical data were retrieved from the TCGA bioportal (<http://www.cbioportal.org/>), containing 20,440 genes and 1,102 samples.

### Pairwise SNP survival analysis

Breast cancer OS analysis was conducted on interactions between SNPs of *ANLN* and *KDR* using the Cox proportional hazard model. The recessive and dominant models were tested in the pairwise SNP association analysis. In the recessive model, the heterozygote is combined with the common homozygote, assuming that the disease-associated phenotype is caused by the concomitant presence of both rare alleles; the dominant model combines the heterozygote with the rare homozygote, assuming that the disease-associating phenotype is caused by the presence of the rare allele. A 10-year breast cancer OS analysis was performed utilizing the 'survival' package ([@b27-or-0-0-7332]) in R software ([@b28-or-0-0-7332]) and a log-rank test was used to assess the statistical significance of the association between SNPs and the clinical outcome. An SNP pair was considered interactive if the P-values of the Cos regression model and the interaction term were both \<0.05 and the number of iterations was \<10.

### Expression quantitative trait loci analysis (eQTL) and function predictions

To identify those genes for which expression was significantly affected by the identified disease-associating SNPs, eQTL analysis was performed using a linear model in R to identify genes associated with complex phenotypes ([@b29-or-0-0-7332]). Whether the allele status (rare homozygote, heterozygote or common homozygote) of a given SNP was linearly associated with the expression of a given gene was assessed. The top 25 percentile of the SNPs with a P-value in the linear model at P\<0.05 were considered eQTLs of a gene.

The combined impact of *ANLN* and *KDR* on genes identified from the eQTL analysis was investigated by stratifying the expression of the genes of interest by the combined expression of *ANLN* and *KDR*. One-way ANOVA and a Least Significant Difference (LSD) post hoc test were applied using R (version 3.5.2) to assess the statistical significance, with P\<0.05 used as the threshold suggestive of a significant trilateral correlation.

The PredictSNP version 2.1 interface ([@b30-or-0-0-7332]) was used to predict the functional interaction network of the SNPs of interest, which uses a series of tools and databases for SNP functional prediction. PredictSNP2 provides easy access to binary predictions and uniform confidence values for the five best-performing prediction tools CADD, DANN, FATHMM, FunSeq2 and GWAVA, and the results obtained from these tools are combined into a consensus score ([@b31-or-0-0-7332]). CADD ([@b32-or-0-0-7332]) estimates the relative pathogenicity of human genetic variants, DANN ([@b33-or-0-0-7332]) uses a deep learning approach for annotating the pathogenicity of genetic variants, GWAVA ([@b34-or-0-0-7332]) is designed for the analysis of regulatory variants, and the FunSeq2 ([@b31-or-0-0-7332]) framework annotates and prioritizes non-coding regulatory variants in cancer.

### Pathway analysis and network construction

In order to investigate the biologically functional consequences introduced by SNPs, pathway enrichment analysis was performed using genes affected by SNPs with statistical significance. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway ([http://www. genome.jp/kegg/](http://www. genome.jp/kegg/)) ([@b35-or-0-0-7332]) and Gene Ontology (GO) term enrichment analyses were performed using the packages clusterProfiler ([@b36-or-0-0-7332]) and org.Hs.eg.db ([@b37-or-0-0-7332]) in R, and Chi-square and Fisher\'s exact tests were used for statistical assessment.

The genes identified from the enriched pathways were collected for gene regulatory network construction using GeneMANIA (<http://www.genemania.org>) ([@b38-or-0-0-7332]), which uses the label propagation algorithm to predict gene-gene interactions at seven levels (co-expression, co-localization, genetic interaction, physical interaction, shared protein domain, pathway and predicted). The interactions at the co-localization, genetic interaction, physical interaction, shared protein domain and pathway levels were used for network construction. The output comprises a regulatory network that uses the user-defined gene list based on databases and publications from multiple resources ([@b38-or-0-0-7332],[@b39-or-0-0-7332]). The 'max resultant genes' was set as five, the 'max resultant attributes' was set as 10, and the GO weighting system was used, which uses biological process (BP)-based, molecular function (MF)-based and cellular component (CC)-based approaches. The complete workflow is illustrated in [Fig. 1](#f1-or-0-0-7332){ref-type="fig"}.

Experimental validation
-----------------------

### Cell culture

One human normal mammary epithelial cell line (MCF10A) and one breast cancer cell line (SUM149PT) were purchased from ATCC and used in the present study. The MCF10A cells were cultured in DMEM/F12 (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 5% charcoal-stripped horse serum (Gibco; Thermo Fisher Scientific, Inc.), 10 µg/ml insulin (PeproTech, Inc.), 20 ng/ml epithelial growth factor (PeproTech, Inc.) and 1.4×10^−6^ mol/l hydrocortisone (PeproTech, Inc.). The SUM149PT cells were cultured in F12 (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 5% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.), 20 µg/ml insulin (PeproTech, Inc.), 1% HEPES (PeproTech, Inc. and 2.8×10^−6^ mol/l hydrocortisone (PeproTech, Inc.). Assay-ready cells were prepared by culturing the cells in a large batch and aliquoting them into ampules that were kept in liquid nitrogen in solution containing 90% FBS and 10% DMSO. Immediately prior to transfection, the cells were thawed and washed with culture medium and the cell number was counted using a hemocytometer (Thermo Fisher Scientific, Inc.).

### SgRNA preparation

pLenti-U6-sgRNA-PGK-Neo (cat. no. K019), piLenti-EF1a-dCas9-SAM (cat. no. K015) and piLenti-EF1a-dCas9-KRAB (cat. no. K203) were purchased from Applied Biological Materials, Inc. The sgRNAs were designed using the publicly available software CHOPCHOP (version 3, <http://chopchop.cbu.uib.no/>) ([@b40-or-0-0-7332]) ([Table SI](#SD1-or-0-0-7332){ref-type="supplementary-material"}), supplemented with the *Bbs*I restriction site, and synthesized from Applied Biological Materials (ABM), Inc. Each sgRNA was added with a sequence complementary to the sticky ends of *Bbs*I, following ligation with the pLenti-U6-sgRNA-PGK-Neo vector digested using *Bbs*I, and the recombinant plasmid was amplified in DH5 *Escherichia coli* (Sigma-Aldrich; Merck KGaA). The plasmids containing sgRNAs were validated using PCR, enzyme digestion and sequencing, and transfected together with piLenti-EF1a-dCas9-SAM or piLenti-EF1a-dCas9-KRAB into cells. The controls were designed as cells concomitantly transfected with all sgRNAs modulating the target gene alone, without piLenti-EF1a-dCas9-SAM or piLenti-EF1a-dCas9-KRAB.

### Cell transfection

A total of 1×10^6^ cells per well were added in 2 ml of culture medium and transferred to 6-well plates (Nalgene, cat. no. 167018). The cells were incubated overnight and were at 70--80% confluence prior to transfection. The medium was replaced with 2 ml serum-free medium prior to transfection. Subsequently, 100 µl Opti-MEM (Gibco; Thermo Fisher Scientific, Inc.) containing 1 µg sgRNA (ABM, Inc.) and 1 µg CRISPR/dCas9 (ABM, Inc.) plasmids were added to 100 µl Opti-MEM containing 6 µl lipo2000 transfection reagent per well and mixed for 15--20 min prior to transfection. The mixture was transferred to 6-well plate and incubated at 37°C for 5--8 h in the presence of 5% CO~2~ (HERA Cell 150i, Thermo Fisher Scientific, Inc.). The serum-free medium was replaced with 2 ml medium containing 10% serum. The cells were incubated at 37°C for 24 h, followed by the addition of G418 and puromycin and incubation for 48 h.

### Reverse transcription-quantitative PCR (RT-qPCR) assay

Following transfection, the cells were collected and extracted for total RNA using TRIzol reagent (Tiangen Biotech Co., Ltd.) 3 days after transfection. The cDNA was synthesized using PrimeScript RT reverse transcriptase as per the manufacturer\'s protocol (Takara Bio, Inc.). The primers used for RT-qPCR analysis are listed in [Table SII](#SD1-or-0-0-7332){ref-type="supplementary-material"}. The qPCR sample consisted of 5 µl 2X SYBR premix ex Taq, 0.4 µl, 10 µm forward and reverse primers, 0.2 µl ROX reference dye, 2 µl cDNA and 2 µl H~2~O. The detailed procedure for RT-qPCR was as follows: Initial denaturation at 95°C for 5 min, 45 cycles of denaturation at 95°C for 5 sec, annealing at 57°C for 30 sec, extension at 72°C for 15 sec. The absorbance value was recorded at the extension stage. The relative expression level was calculated using the 2^−∆∆Cq^ method ([@b41-or-0-0-7332]). All RT-qPCR experiments were performed using the ABI StepOnePlus Real-Time PCR system (ABI; Thermo Fisher Scientific, Inc.).

### Statistical analysis

One-way ANOVA coupled with Scheffe\'s post hoc test were conducted using R software (version 3.5.2) to evaluate the significance of changes in the expression level of *ANLN* or *KDR* following genetic modulations compared with each corresponding control where the P-value threshold was set as 0.05.

Results
=======

### SNPs of ANLN and KDR synergistically affect breast cancer survival rates

Pairwise SNP survival analysis was performed using multivariate Cox regression models and statistical significance was assessed using the likelihood ratio test. Of all 260 SNP pairs, two pairs were identified with significant synergistic effects on breast cancer survival rate from the dominant model ([Fig. 2A-D](#f2-or-0-0-7332){ref-type="fig"}). The two pairs were *ANLN*:rs12535394 and *KDR*:rs11133360 and *ANLN*:rs10275489 and *KDR*:rs11941492. The concurrent presence of both rare homozygotes in the *ANLN*:rs12535394 and *KDR*:rs11133360 SNP pair is associated with favorable clinical outcomes (HR=0.52, P=0.03), whereas the *ANLN*:rs10275489 and *KDR*:rs11941492 SNP pair was associated with poor breast cancer prognosis (HR=1.8, P=0.05). These four SNPs are non-linkage disequilibrium (LD) linked and were defined as disease-associated SNPs. Of these four disease-associated SNPs, *KDR*:rs11133360 was identified as intronic (chr4:55116585) and its rare allele was predicted as deleterious by the FunSeq2 and GWAVA tools ([Table I](#tI-or-0-0-7332){ref-type="table"}).

### Genes affected by disease-associated SNPs

The eQTL analysis of the four disease-associated SNPs resulted in 401 genes with KEGG annotations ([Tables SIII](#SD1-or-0-0-7332){ref-type="supplementary-material"} and [SIV](#SD1-or-0-0-7332){ref-type="supplementary-material"}; [Figs. 3](#f3-or-0-0-7332){ref-type="fig"} and [4](#f4-or-0-0-7332){ref-type="fig"}). Amongst these genes, the expression of microtubule-associated protein 10 \[*MAP10*; correlation (cor)=0.554, P=0.001\] was significantly positively correlated with the number of rare alleles of *ANLN*:rs12535394 (P=0.007, [Fig. 3A](#f3-or-0-0-7332){ref-type="fig"}), and interacted with *ANLN* at the transcriptional level to predict breast cancer OS ([Fig. 4C and D](#f4-or-0-0-7332){ref-type="fig"}). Furthermore, the overexpression of *MAP10* conveyed favorable clinical outcomes (HR=0.73, P=9.5E-5, [Fig. 4A](#f4-or-0-0-7332){ref-type="fig"}), but was associated with poor breast cancer OS when the expression of *ANLN* was concomitantly low (HR=2.66, P=0.0062, [Fig. 4C](#f4-or-0-0-7332){ref-type="fig"}). The expression of *MAP10* was not directly associated with that of *ANLN* (cor=0.04, P=0.198, [Fig. 3B](#f3-or-0-0-7332){ref-type="fig"}), but was expressed at a low level under the concomitant low expression of both *ANLN* and *KDR* (P=9.3E-5, [Fig. 3C](#f3-or-0-0-7332){ref-type="fig"}), further suggesting the involvement of *MAP10* in the synergy created between *ANLN* and *KDR* at the transcriptional level. Zinc finger protein 133 (*ZNF133*) was the top gene whose expression was significantly associated with the allele status of *ANLN*:rs12535394. The SNP rare allele was associated with a high and statistically significant expression of *ZNF133* (P=1.4E-5). The rare allele status of this SNP was positively correlated with the expression of *ZNF133* (cor=0.14, P=0.3.8E-6, [Fig. 3D](#f3-or-0-0-7332){ref-type="fig"}) and negatively correlated with the expression of *ANLN*. The expression of *ZNF133* was stratified into distinct expression levels by the expression of *ANLN* (P=0.0001); the expression of *ZNF133* and expression of *ANLN* were negatively correlated (cor=−0.22, P=1.6E-12, [Fig. 3E](#f3-or-0-0-7332){ref-type="fig"}), suggesting a negative correlation between the rare allele of *ANLN*:rs12535394 and the expression of *ANLN*. Such a negative association was exemplified by the low expression of *KDR*, i.e., the concomitant underexpression of *ANLN* and *KDR* was associated with the overexpression of *ZNF133* (P=3.23E-9, [Fig. 3F](#f3-or-0-0-7332){ref-type="fig"}). Given the favorable clinical outcome associated with the high expression of *ZNF133* (HR=0.76, P=7.8E-7, [Fig. 4E](#f4-or-0-0-7332){ref-type="fig"}), it was reasoned that the *ANLN* rare allele is associated with desirable breast cancer relapse-free survival. Furthermore, *ZNF133* interacted with *ANLN* to influence breast cancer OS at the transcriptional level ([Fig. 4G and H](#f4-or-0-0-7332){ref-type="fig"}), providing further evidence of the association between the allele status of *ANLN*:rs12535394 and the expression and prognostic value of *ANLN*. Similar to *ZNF133, C14ORF80* was the top gene whose expression was significantly positively correlated with the rare allele expression of *KDR*:rs11133360 (cor=0.2, P=0.001). The SNP rare allele was significantly associated with a high expression of *C14ORF80* (P=0.006, [Fig. 5A](#f5-or-0-0-7332){ref-type="fig"}) and negatively correlated with the expression of *KDR* (cor=−0.4, P\<2.2E-16). The expression of *C14ORF80* was stratified into distinct expression levels by the expression of *KDR* (P\<2.2E-16, [Fig. 5B](#f5-or-0-0-7332){ref-type="fig"}), indicating a negative correlation between the rare allele of *KDR*:rs11133360 and expression of *KDR*. In addition, the concomitant high expression of *ANLN* and *KDR* was associated with a high expression of *C14ORF80* (P=6E-11, [Fig. 5C](#f5-or-0-0-7332){ref-type="fig"}), which was prognostic of favorable breast cancer OS (HR=0.61, P=0.0279, [Fig. 5D](#f5-or-0-0-7332){ref-type="fig"}), suggesting the favorable prognostic value of *KDR*:rs11133360. Furthermore, *C14ORF80* was shown to interact with *KDR* to influence breast cancer OS at the transcriptional level ([Fig. 5E and F](#f5-or-0-0-7332){ref-type="fig"}), supporting the association between the allele status of *KDR*:rs11133360 and the expression and prognostic value of *KDR*. The rare alleles of *ANLN*:rs12535394 and *KDR*:rs11133360 have been implicated with favorable clinical outcomes, which is consistent with the observations at the SNP level in the present study (HR=0.52, P=0.0313, [Fig. 2A](#f2-or-0-0-7332){ref-type="fig"}), and have been associated with a low expression of *ANLN* and *KDR* at the transcriptional level, which was in accordance with what was observed at the transcriptional level in the present study ([Fig. 2C](#f2-or-0-0-7332){ref-type="fig"}).

No genes were found to be significantly associated with the *ANLN*:rs10275489 allele status and expression of *ANLN*, or with the *KDR*:rs11941492 allele status and expression of *KDR*.

### Pathway and network construction using eQTL genes influenced by disease-associated SNPs

Pathway enrichment analysis showed that these genes were significantly enriched in the primary immunodeficiency disorder (PID) pathways (hsa05340, P=10^−4^; [Fig. 6](#f6-or-0-0-7332){ref-type="fig"}). Genes enriched in hsa05340 included *ORAI1, DCLRE1C, IL2RG, RFXANK, ADA, AIRE, CD19, TNFRSF13C* and *ZAP70*. The expression of six of these nine genes, i.e., *ADA* (P=0.0141), *IL2RG* (P=0.0284), *DCLRE1C* (P=2E-16), *ORAI1* (P=0.0141), *RFXANK* (P=2E-16) and *TNFRSF13C* (P=0.0081) varied significantly across the groups stratified by the joint assessment of *ANLN* and *KDR* expression ([Fig. 7A-I](#f7-or-0-0-7332){ref-type="fig"}). Significant pairs were 'high_high vs. low_high', 'high_low vs. low_high', 'high_low vs. low_low' in *ADA*, 'high_high vs. low_high' and 'high_high vs. low_low' in *IL2RG*, 'high_high vs. low_high', 'high_low vs. low_high', 'high_high vs. low_low', 'high_low vs. low_low' in *DCLRE1C*, 'high_high vs. high_low', 'high_high vs. low_high', 'high_high vs. low_low', 'high_low vs. low_high', 'low_high vs. low_low' in *ORAI1*, 'high_high vs. high_low', 'high_low vs. low_high', 'high_high vs. low_low', 'high_low vs. low_low', 'low_high vs. low_low' in *RFXANK*, and 'high_low vs. low_high' and 'high_low vs. low_low' in *TNFRSF13C*. All statistical P-values from ANOVA and the LSD test for pairwise comparisons are listed in [Table SV](#SD1-or-0-0-7332){ref-type="supplementary-material"}.

The network constructed from GeneMANIA using *KDR, ANLN* and the genes affected by the disease-associated SNPs as the initial input exhibited different topological structures when constructed using different GO-weighted approaches ([Fig. 8A-C](#f8-or-0-0-7332){ref-type="fig"}). In addition to *ANLN* and *KDR*, the network included *PTEN, PDGFRB, ZAP70, ORAI1, STIM1, TNFSF13B* and *TNFRSF13C* when BP was used as the weighting approach, *FYN, ZAP70, IL2RG* and *AIRE* when the weighting criteria was based on MF, and *PTEN, MEN1, TNFRSF13C, TNFSF13B, STIM1, ORAI1* and *ZAP70* when CC was used in weighting. The network was segregated into two areas when CC was used as the weighting method.

### Experimental validation of interactions between ANLN and KDR

In the *in vitro* experiments, *ANLN* did not affect the expression of *KDR* in the MCF10A normal breast epithelial cells (P=0.27 when *ANLN* was upregulated, P=0.09 when *ANLN* was downregulated, [Fig. 9B](#f9-or-0-0-7332){ref-type="fig"}), but positively regulated the expression of *KDR* in the SUM149PT breast cancer cells (P=2.74E-6 when *ANLN* was upregulated, P=1.47E-2 when *ANLN* was downregulated, [Fig. 9A](#f9-or-0-0-7332){ref-type="fig"}). *KDR* had an opposing effect on the expression of *ANLN* in the MCF10A cells (P=2.82E-4 when *KDR* was upregulated, P=3.36E-9 when *KDR* was downregulated, [Fig. 9B](#f9-or-0-0-7332){ref-type="fig"}), but positively influenced the expression of *ANLN* in SUM149PT cells (P=1.82E-7 when *KDR* was upregulated, P=1.25E-4 when *KDR* was downregulated, [Fig. 9A](#f9-or-0-0-7332){ref-type="fig"}). All statistical P-values from ANOVA with Scheffe\'s test for all pairwise comparisons are listed in [Table SVI](#SD1-or-0-0-7332){ref-type="supplementary-material"}.

Discussion
==========

Through pairwise interactive OS analyses of the SNPs of *ANLN* and *KDR*, the present study identified four disease-associated SNPs (*ANLN*:rs12535394, *KDR*:rs11133360, *ANLN*:rs10275489 and *KDR*:rs11941492), where *ANLN*:rs12535394 paired with *KDR*:rs11133360, and *ANLN*:rs10275489 paired with *KDR*:rs11941492 to synergistically influence the clinical outcome of breast cancer. Of the two SNP pairs, the allele status of *ANLN*:rs12535394 and *KDR*:rs11133360 was associated with the expression of *ANLN* and *KDR*, respectively, via *ZNF133* and *C14ORF80*, and were synergistically prognostic of a favorable clinical outcome in breast cancer.

The quantity of the rare allele of *ANLN*:rs12535394 was positively associated with the expression of *ZNF133* and negatively correlated with the expression of *ANLN* with statistical significance, and the overexpression of *ZNF133* was prognostic for a favorable clinical outcome. These results indicate that the rare allele of *ANLN*:rs12535394 is protective and associated with a low expression of *ANLN* via *ZNF133*. Therefore, *ZNF133* interacts with *ANLN* to affect breast cancer survival, in which the protective effect of the overexpression of *ZNF133* is amplified under the high expression of *ANLN* ([Fig. 4F and H](#f4-or-0-0-7332){ref-type="fig"}). Few *ZNF133* functionalities have been reported in cancer, but the transcriptionally suppressive activity of zinc finger protein has been reported for its overamplification in neuroblastoma cells ([@b42-or-0-0-7332]) and overexpression in chronic myeloid leukemia ([@b43-or-0-0-7332]) in two independent high-throughput studies. These findings collectively suggest the tissue-specific pathological functionalities of *ZNF133*, i.e., *ZNF133* is tumor suppressive in breast cancer, particularly in situations under a high expression of *ANLN*, which warrants experimental validation.

Furthermore, the quantity of the rare allele of *ANLN*:rs12535394 was positively associated with the expression of *MAP10*. MAP family proteins regulate microtubule properties ([@b44-or-0-0-7332]) and serve an important role in an array of cellular processes, including cell division, cell motility, intracellular trafficking, microtubule stability and cell morphology maintenance ([@b45-or-0-0-7332]). The overexpression and post-translational modifications of MAPs contribute to the dysregulation of microtubule dynamics and the development of serious diseases including human breast cancer ([@b46-or-0-0-7332]--[@b50-or-0-0-7332]). In the present study, the overexpression of MAP10 was not pathologically relevant but conveyed a poor clinical outcome when the expression of *ANLN* was low ([Fig. 4C](#f4-or-0-0-7332){ref-type="fig"}), suggesting the conditional prognostic value of *MAP10* in breast cancer, i.e., protective when the expression of *ANLN* is high and risky when the expression of *ANLN* is low.

Similarly, the quantity of the rare allele of *KDR*:rs11133360 was positively associated with the expression of *C14ORF80*, which was significantly negatively correlated with the expression of *KDR*, and the overexpression of *C14ORF80* was prognostic for favorable breast cancer OS ([Fig. 5](#f5-or-0-0-7332){ref-type="fig"}); these results indicate that the rare allele of *KDR*:rs11133360 is negatively associated with the expression of *KDR* via the overexpression of *C14ORF80* and conveys desirable prognostic value on the clinical outcome of breast cancer. The prognostic value of *C14ORF80* was increased under a low expression of *KDR*, suggesting interactions between these genes. *C14ORF80*, also termed *TEDC1*, has not previously been annotated nor shown to be associated with cancer. There are currently no publications available on this gene from the Web of Science. The present study highlights the potential prognostic role of *C14ORF80* in predicting breast cancer survival rates and its involvement in *KDR*-mediated tumor angiogenesis.

The synergy created amongst SNPs affecting breast cancer survival may involve more than two SNPs. However, it is plausible to include fewer indicators in the diagnostic panel for the sake of clinical convenience. Therefore, pairwise interaction models were used initially in the present study to examine the potential synergy; establishing multivariate models was a consideration if no specific results were obtained from the pairwise interaction analysis.

A total of 401 genes were obtained for which the expression profiles were significantly affected by the disease-associated SNPs and these were annotated in the KEGG. These genes were enriched in the PID pathway. PID is a diverse group of illnesses characterized by defects in the function of one or more components of the immune system, which predisposes affected individuals to an increased incidence of infections, autoimmunity and malignancies ([@b51-or-0-0-7332]). Patients with PID are at increased risk of developing malignancies compared with healthy individuals in the population ([@b52-or-0-0-7332]), and the overall risk for developing cancer in patients with PID was estimated to be up to 25% ([@b53-or-0-0-7332]). The majority of these identified genes have immune-related functionalities. For example, *ADA* encodes an enzyme that increases the rate of hydrolyzation of adenine to inosine and serves a potential role in the development of the immune system and maturation of mammalian cells ([@b54-or-0-0-7332]). *IL2RG* encodes a protein that is an important signaling component of numerous interleukin receptors, including those of interleukin-2, −4, −7 and −21. Importantly, of the nine genes involved in the PID pathway and transcriptionally associated with the rare allele status of these disease-associated SNPs, six are significantly affected by interactions between *ANLN* and *KDR* at the transcriptional level. Together, these results suggest the prominent role of the immune response in the synergies created between *ANLN* and *KDR* on their prognostic value in breast cancer survival, which may be the driving force behind the life/death control of cells and angiogenesis/metastasis transition during carcinogenesis.

The network constructed using *ANLN, KDR* and genes affected by the identified disease-associated SNPs as the input revealed differential networks depending on the weighting approaches used. *ANLN* and *KDR* were connected through *PTEN* and *PDGFRB* when BP weighting was used, were linked through *FYN* when MF weighting was used, and did not connect when CC was used as the weighting approach. The differential topological structures obtained through the use of different GO weighting approaches suggest that *ANLN* and *KDR* interact and create synergies in BPs and MFs, but do not share the use or functionalities of CCs. *PDGFRB* encodes a typical receptor tyrosine kinase, PDGFRβ, which physically interacts with PTEN according to an *in situ* proximity ligation assay ([@b55-or-0-0-7332]). *PTEN* is a representative molecule in PI3K/PTEN signaling that shares the same biological pathway with *ANLN* ([@b7-or-0-0-7332]). FYN physically interacts with ANLN according to the human interactome generated from quantitative proteomics ([@b56-or-0-0-7332]), and *FYN* shares similar oncological roles with *ANLN*, i.e., the overexpression of *FYN* promotes cell proliferation, migration and invasion in breast cancer cells ([@b57-or-0-0-7332],[@b58-or-0-0-7332]).

Experimentally the present study showed that *ANLN* and *KDR* interact in normal breast epithelial cells and breast cancer cells. *ANLN* alterations did not affect the expression of *KDR*, however, modulating the expression of *KDR* led to the inverse regulation of *ANLN* in normal breast epithelial cells, suggesting that *KDR* is an upstream regulator of *ANLN* under normal conditions. When the cells were attracted in the malignant state, altering either ANLN or KDR led to regulation of the other gene in the same direction, suggesting the formation of a feed-forward loop that may lead to oncological signal amplification. This is clinically plausible as the concomitant low expression of *ANLN* and *KDR*, which is associated with favorable breast cancer survival, was easily achieved by targeting *ANLN* or *KDR* alone, with *ANLN* being a more plausible therapeutic target than *KDR* as it is a downstream effector of *KDR* in non-malignant cells. By contrast, a change in the interaction mode of the two genes in normal and cancer cells implicates the importance of the *ANLN-KDR* interaction in the transition of cells between normal and cancerous states and on breast cancer clinical outcomes. Whether *ANLN-KDR* interactions constitute to or are the consequence of carcinogenesis remain to be elucidated.

The present study used a triple-negative breast cancer cell line to experimentally validate interactions between *ANLN* and *KDR*, as the main effect of the synergy is driven by that in triple-negative breast cancer ([Fig. S1](#SD1-or-0-0-7332){ref-type="supplementary-material"}). In addition, the use of SNP/gene pairs with synergistic prognostic values for triple-negative breast cancer carriers is more plausible clinically than other subtypes, as the triple-negative subtype is highly malignant and lacks targeted therapies ([@b59-or-0-0-7332],[@b60-or-0-0-7332]). However, investigating the association between *ANLN-KDR* synergy and breast cancer subtyping is worthwhile and remains the subject of future investigations.

In conclusion, the concurrent presence of both rare homozygotes in *ANLN*:rs12535394 and *KDR*:rs11133360 was identified as prognostic for favorable survival in breast cancer. The quantity of the rare allele of *ANLN*:rs12535394 was negatively associated with the expression of *ANLN*, and that of *KDR*:rs11133360 was negatively associated with the expression of *KDR*, both of which are protective. Novel roles of genes that bridge the gap between SNPs and corresponding genes were revealed and merit in-depth investigation, including the potential tissue-specific tumor suppressive roles of *ZNF133* in breast cancer, the conditional effects of *MAP10* on breast cancer survival rates and the possible suppressive role of *C14ORF80* (a gene not being annotated) during tumor angiogenesis. Pathways controlling cell proliferation/apoptosis and angiogenesis/migration genetically interact and ultimately influence immune responses and patient clinical outcomes, suggesting the intrinsic connection amongst cancer hallmarks and the prominent role for immunotherapy in cancer state transition. Experimental validations confirmed the roles of the *ANLN-KDR* interaction in the transition of cells between normal and cancerous states and in breast cancer prognosis, and implicate the therapeutic potential of *ANLN*.
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![Workflow of the study. The square boxes represent data or results and the diamond boxes show the analytical processes. Values shown within square brackets represent the quantity of the results obtained. SNPs, single nucleotide polymorphisms; TCGA, The Cancer Genome Atlas; OS, overall survival; eQTL, expression quantitative trait loci analysis.](or-42-06-2255-g00){#f1-or-0-0-7332}

![Kaplan-Meier plots showing the prognostic value of the identified disease-associated SNP pair and the corresponding gene pair. (A) Overall breast cancer survival for the SNP pair ANLN:rs12535394 and KDR:rs11133360. (B) Overall breast cancer survival for the SNP pair ANLN:rs10275489 and KDR:rs11941492. 'SNPs=rare' refers to rare homozygote, 'SNPs=common' represents either a common homozygote or heterozygote. (C) Overall breast cancer survival with concomitantly low expression of ANLN and KDR. 'Genes=low' refers to concomitant low expression of both genes, 'Genes=not low' includes cases where expression of at least one gene is not low. (D) Overall breast cancer survival with concomitantly high expression of ANLN and KDR. 'Genes=high' refers to concomitant high expression of both genes, 'Genes=not high' includes cases where expression of at least one gene is not high. SNP, single nucleotide polymorphism; ANLN, anillin actin-binding protein; KDR, kinase insert domain receptor.](or-42-06-2255-g01){#f2-or-0-0-7332}

![Evidence of associations between ANLN:rs12535394 and the expression of ANLN. (A) Association between the allele status of ANLN:rs12535394 and the gene expression of MAP10. (B) Expression of MAP10 stratified by that of ANLN. (C) Expression of MAP10 stratified by the joint expression of ANLN and KDR. (D) Association between the allele status of ANLN:rs12535394 and the gene expression of ZNF133. (E) Expression of ZNF133 stratified by that of ANLN. (F) Expression of ZNF133 stratified by the joint expression of ANLN and KDR. 0, 1 and 2 represent the numbers of rare alleles in ANLN:rs12535394. The Cancer Genome Atlas data was used for producing all panels. ANLN, anillin actin-binding protein; KDR, kinase insert domain receptor; MAP10, microtubule-associated protein 10; ZNF133, zinc finger protein 133.](or-42-06-2255-g02){#f3-or-0-0-7332}

![Prognostic value of key genes associated with ANLN:rs12535394 and their impact on the interactions between ANLN and KDR on breast cancer survival. (A) Prognostic value of MAP10 on breast cancer relapse-free survival, drawn using Kaplan Meier Plotter. (B) Prognostic value of MAP10 on breast cancer overall survival drawn using TCGA data. (C) Expression of MAP10 on breast cancer survival under ANLN low expression, drawn using TCGA data. (D) Expression of MAP10 on breast cancer survival under high expression of ANLN, drawn using TCGA data. (E) Prognostic value of ZNF133 on breast cancer relapse-free survival, drawn using Kaplan Meier Plotter. (F) Prognostic value of ZNF133 on breast cancer overall survival, drawn using TCGA data. (G) Expression of ZNF133 on breast cancer survival under low expression of ANLN, drawn using TCGA data. (H) Expression of ZNF133 on breast cancer survival under high expression of ANLN, drawn using TCGA data. ANLN, anillin actin-binding protein; KDR, kinase insert domain receptor; MAP10, microtubule-associated protein 10; ZNF133, zinc finger protein 133; TCGA, The Cancer Genome Atlas.](or-42-06-2255-g03){#f4-or-0-0-7332}

![Evidence of associations between KDR:rs11133360 and the expression of KDR and the prognostic value of a key gene associated with ANLN:rs12535394 and its impact on interactions between ANLN and KDR on breast cancer survival. (A) Association between the allele status of KDR:rs11133360 and the gene expression of C14ORF80. 0, 1 and 2 represents the number of rare alleles in KDR:rs11133360. (B) Expression of C14ORF80 stratified by that of KDR. (C) Expression of C14ORF80 stratified by the joint expression of ANLN and KDR. (D) Prognostic value of C14ORF80 on breast cancer overall survival, drawn using TCGA data. (E) Expression of C14ORF80 and breast cancer survival under low expression of KDR. (F) Expression of C14ORF80 and breast cancer survival under high expression of KDR. TCGA data was used for drawing all panels. The prognostic value of C14ORF80 on breast cancer overall survival drawn using Kaplan Meier Plotter is not present as this gene was not available in that database. ANLN, anillin actin-binding protein; KDR, kinase insert domain receptor; TCGA, The Cancer Genome Atlas.](or-42-06-2255-g04){#f5-or-0-0-7332}

![Pathway enrichment analysis of genes with eQTL associations with identified disease-associated SNPs. (A) Enriched pathways of genes with eQTL associations with identified disease-associated SNPs. The 'primary immunodeficiency pathway (hsa05340)' was enriched from the Kyoto Encyclopedia of Genes and Genomes ([@b36-or-0-0-7332]) and is illustrated. Genes whose expression were quantitatively associated with the identified disease-associating SNPs are highlighted in red. Cell developmental stages are annotated using green boxes. HSC, hematopoietic stem cell; DP, CD4^+^CD8^+^; NK, natural killer; eQTL, expression quantitative trait loci.](or-42-06-2255-g05){#f6-or-0-0-7332}

![Expression of PID pathway genes (A-I) with expression quantitative trait loci associations stratified by the expression of ANLN and KDR. ANOVA and the LSD post hoc test were used to assess the statistical significance of variations in the expression of one PID pathway gene stratified by the joint expression of ANLN and KDR. The expression of 9 genes in total was presented in boxplot where data were stratified by high/low expression of ANLN and KDR. PID, primary immunodeficiency disorder; ANLN, anillin actin-binding protein; KDR, kinase insert domain receptor.](or-42-06-2255-g06){#f7-or-0-0-7332}

![Networks of ANLN and KDR. Networks were constructed using GeneMania ([@b39-or-0-0-7332]) with (A) molecular function, (B) biological process, (C) cellular component as the weighting strategies. ANLN, anillin actin-binding protein; KDR, kinase insert domain receptor.](or-42-06-2255-g07){#f8-or-0-0-7332}

![Interactions between ANLN and KDR as validated using SUM149PT and MCF10A cells. (A) Expression of KDR on modulating the expression of ANLN and the expression of ANLN after modulating KDR in SUM149PT breast cancer cells. (B) Expression of KDR after modulating the expression of ANLN and the expression of ANLN after modulating KDR in MCF10A normal breast epithelial cells. Bars represent the mean ± SD from at least three independent experiments (\*0.01\<P\<0.05 and \*\*P\<0.01 by ANOVA and Scheffe\'s post hoc test). Gene expression in each experimental group was normalized by the corresponding control. ANLN-up, dCas9-SAM and sgRNA upregulating ANLN were co-transfected into SUM149PT or MCF10A cells; ANLN-down, dCas9-KRAB and sgRNA downregulating ANLN co-transfected into cells; KDR-up, dCas9-SAM and sgRNA upregulating KDR co-transfected into cells; KDR-down, dCas9-KRAB and sgRNA downregulating KDR co-transfected into cells; Control, sgRNAs up- and downregulating ANLN and KDR co-transfected into cells; ANLN, anillin actin-binding protein; KDR, kinase insert domain receptor.](or-42-06-2255-g08){#f9-or-0-0-7332}

###### 

Effects of the identified disease-associated single nucleotide polymorphisms predicted using PredictSNP2.

                KDR: rs11133360 (position: chr4:55116585)   KDR: rs11941492 (position: chr4:55112043)                             
  ------------- ------------------------------------------- ------------------------------------------- ------ --------- -------- ------
  PredictSNP2   Neutral                                     −1                                          0.88   Neutral   −1       0.88
  CADD          Neutral                                     8.242                                       0.76   Neutral   3.493    0.82
  DANN          Neutral                                     0.3796                                      0.8    Neutral   0.5371   0.82
  FATHMM        Neutral                                     0.1461                                      0.91   Neutral   0.0614   0.95
  FunSeq2       Deleterious                                 2.3903                                      0.67   --        0.7762   0.45
  GWAVA         Deleterious                                 0.49                                        0.64   Neutral   0.15     0.79

For KDR: rs11133360 and KDR: rs11941492, the common allele was C, the rare allele was T and the region was intronic. PredictSNP2 provides easy access to other tools, including CADD, DANN, FATHMM, FunSeq2 and GWAVA, with binary predictions and uniform confidence values as the outputs.
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